OGN Q1 2025

Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Organon delivered a stronger-than-expected first quarter, posting adjusted EPS of $1.02 against a consensus estimate of $0.89, a beat of 14.17%, even as reported revenue of $1.51 billion slipped 6.7% year-over-year under the weight of loss-of-exclusi… Read more Organon delivered a stronger-than-expected first quarter, posting adjusted EPS of $1.02 against a consensus estimate of $0.89, a beat of 14.17%, even as reported revenue of $1.51 billion slipped 6.7% year-over-year under the weight of loss-of-exclusivity headwinds on Atozet in key European markets and ongoing generic pressure across mature products. Revenue edged just above the $1.51 billion consensus by 0.32%, with the U.S. Growing 11% to $412 million providing a meaningful counterbalance to broad international declines. The quarter's defining storyline, however, was a sharp dividend reduction from $0.28 to $0.02 per share quarterly, a deliberate pivot toward accelerated deleveraging as the company targets a net leverage ratio below 4.0x by year-end from roughly 4.3x currently. Women's Health was the portfolio's bright spot, with Nexplanon growing 14% on a constant-currency basis and remaining on track for over $1 billion in 2025 revenue, supported by creative marketing efforts targeting younger consumers. Organon affirmed full-year 2025 guidance, including revenue of $6.13 billion to $6.33 billion and adjusted EBITDA margin of 31% to 32%.